Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Reviewα-helical CRF 9-41
Description: CRF antagonist
Alternative Names: α-helical-Corticotropin-Releasing Factor 9-41
Purity: ≥95% (HPLC)
Biological Activity for α-helical CRF 9-41
α-helical CRF 9-41 is a corticotropin-releasing factor receptor antagonist (Ki values are 17, 5 and 0.97 at human CRF1, rat CRF2α and mouse CRF2β receptors respectively).
Licensing Information
Sold with the permission of the SALK Institute
Technical Data for α-helical CRF 9-41
| M. Wt | 3827 |
| Formula | C166H274N46O53S2 |
| Sequence |
DLTFHLLREMLEMAKAEQEAEQAALNRLLLEEA (Modifications: Ala-33 = C-terminal amide) |
| Storage | Store at -20°C |
| Purity | ≥95% (HPLC) |
| CAS Number | 90880-23-2 |
| PubChem ID | 44593730 |
| InChI Key | PNGVJHODDQMQKT-GVKLFNHCSA-N |
| Smiles | [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(N)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for α-helical CRF 9-41
References for α-helical CRF 9-41
References are publications that support the biological activity of the product.
Kask et al (1997) Alpha-helical(9-41) revents anxiogenic-like effect of NPY Y1 receptor antagonist BIBP3226. NeuroReport 8 3645 PMID: 9427342
Perrin and Vale (1999) Corticotropin releasing factor receptors and their ligand family. Ann.N.Y.Acad.Sci. 885 312 PMID: 10816663
Swerdlow et al (1989) Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by α-helical CRF (9-41). Neuropsychopharmacology 2 285 PMID: 2610824
View Related Products by Target
View Related Products by Product Action
Keywords: alpha-helical CRF 9-41, alpha-helical CRF 9-41 supplier, CRF, receptor, antagonists, Corticotropin-Releasing, Factor, Non-Selective, Receptors, α-helical, alpha-helical, 9-41, a-helical, CRF9-41, a-helical-Corticotropin-Releasing, Factor9-41, Non-selective, 1184, Tocris Bioscience
2 Citations for α-helical CRF 9-41
Citations are publications that use Tocris products. Selected citations for α-helical CRF 9-41 include:
Wang et al (2014) Involvement of CRH and hCG in the induction of aromatase by cortisol in human placental syncytiotrophoblasts. Placenta 35 30 PMID: 24239159
Jia et al (2013) Role of nesfatin-1 in a rat model of visceral hypersensitivity. J Immunol 19 3487 PMID: 23801843
Reviews for α-helical CRF 9-41
There are currently no reviews for this product. Be the first to review α-helical CRF 9-41 and earn rewards!
Have you used α-helical CRF 9-41?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.